Journal Information
Transthyretin amyloidosis
Edited by Dr. Juan González Moreno - Hospital Universitario, Spain. Dra. Inés Losada López - Hospital Universitario, Spain
The Special Issue on ATTR amyloidosis aims to provide an updated vision of a disease with two main forms, a hereditary one (ATTRv) and acquired one (ATTRwt). Even if the first one is considered a rare disease, in Spain there are two endemic foci (Valverde del Camino, in Huelva, and Mallorca in the Balearic Islands), that currently represent the 5th major worldwide focus in patient density for this illness. The mutation with the highest prevalence is the Val50Met, which is also the mutation present in the Spanish foci. Despite this being a multisystemic disease, it will usually appear as a very aggressive polyneuropathy. The prevalence of the acquired form ATTRwt, is rising and it is estimated that up to the 13% of the patients with heart failure with preserved ejection fraction admitted in Spanish hospitals might have this cardiac storage disease. This pathology-focused special issue is relevant due to the recent advances in the diagnosis and treatment of this disease.
Incidence and causes of hospitalization in patients with transthyretin (ATTR-CA) and light chain (AL-CA) cardiac amyloidosis
Daniel Enríquez-Vázquez, Carlos Gómez-Martín, Gonzalo Barge-Caballero, Eduardo Barge-Caballero, Manuel López-Pérez, Raquel Bilbao-Quesada, Eva González-Babarro, Inés Gómez-Otero, ... María G. Crespo-Leiro
Med Clin. 2024;162:e1-e7
Early diagnosis in ATTRv amyloidosis, how early is enough? How early is possible?
Isabel Conceição
Med Clin. 2024;162:e70-e73
Real life experience of tafamidis for the treatment of Spanish patients with Val30Met transthyretin amyloidosis with polyneuropathy
Maria Antonia Ribot Sanso, Adrián Rodriguez Rodriguez, Laura Martínez Vicente, Teresa Sevilla, Cristina Borrachero Garro, Julian Fernández Martín, Adrián Antón Vicente, Moises Morales de la Prida, ... Juan González-Moreno
Med Clin. 2024;162:e27-e32
Value of multi-modality small fiber assessments in a genotypically diverse cohort of transthyretin-related amyloidosis in the early stages of disease
Monica Alcantara, Shabber Mannan, James de la Cruz, Vera Bril
Med Clin. 2024;162:e64-e69
Open Article
Update in ‘wild-type’ transthyretin cardiac amyloidosis: Clinical guide for its diagnosis and treatment
Lorena Herrador, Sergi Yun, José González-Costello
Med Clin. 2024;163:e36-e43
Recommendations update for the diagnosis and treatment of transthyretin variant amyloidosis (ATTRv)
Juan González-Moreno, Lucía Galán Dávila, Esther Gonzalez-Lopez, Isabel Conceiçao
Med Clin. 2024;163:e69-e77